sellWeak
Allison Dorval sold $6,343 of VERV
Chief Financial Officer at Verve Therapeutics, Inc.. 554 shares at an average of $11.45, traded Nov 29, 2023, filed Dec 1, 2023.
Warning score
12Value
$6,343
554 shares
Holdings after
4,060
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$6k at market
- +5Share of holdings soldSold 12% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-067358, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 29, 2023 | MOption exercise Common Stock | +1,875 | - | - | 4,614 | Dec 1, 2023 |
| Nov 29, 2023 | SOpen-market sale Common Stock | -554 | $11.45 | $6,343 | 4,060 | Dec 1, 2023 |
| Nov 29, 2023 | MOption exercise Restricted Stock Unitsderivative | -1,875 | $0.00 | $0 | 3,750 | Dec 1, 2023 |
Related signals
Other insiders at Verve Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $11k 2,681 shares | -1% | |
| 7Weak | Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $14k 3,350 shares | -20% | |
| 11Weak | Verve Therapeutics, Inc. | Sekar Kathiresan Chief Executive Officer | $41k 9,822 shares | -3% | |
| 0Weak | Verve Therapeutics, Inc. | Troy Lister Chief Scientific Officer | $9,084 2,189 shares | -24% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 2,777 shares | -14% | |
| 0Weak | Verve Therapeutics, Inc. | Jason Politi Chief Technical Ops. Off. | $13k 3,235 shares | -19% | |
| 7Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $3,130 555 shares | -9% | |
| 39Weak | VERVbuy Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $476k 76,000 shares | +29% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 1,514 shares | -15% | |
| 48Moderate | VERVbuy Verve Therapeutics, Inc. | Krishna Yeshwant director, owner | $18M 1,800,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.